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hypertensive patients. METHODS: The study cohort is com-
posed of 152 hypertension patients, a subset of all those 498
enrolled to date in the Baltimore Partnership Programs to Reduce
Cardiovascular disparities study, and who have one year follow-
up. The study follows a 2 × 2 factorial nested case-control design:
patients and their physicians were randomly assigned to either
intervention or control group, where only the intervention group
received patient/physician education. Blood pressure (BP) was
measured at one year follow up. We used multiple regressions to
assess the effect of the interventions on systolic blood pressure
(SBP) change, from baseline to one year follow-up. The model is
adjusted for sociodemographics, patient knowledge score in
hypertension (per “High Blood Pressure Survey”, Matins D,
2001) and concomitant diabetes. RESULTS: Most patients are
Black (86.2), female (67.1%), and under 65 years of age
(71.7%). Mean pre- and post BP are 145/87 mmHg and 136/80
mmHg, respectively. SBP reduction is signiﬁcantly larger in
patients under 65 (p = 0.04), and marginally signiﬁcant in those
who received intervention (p = 0.06) and in those whose physi-
cians participated in the education sessions (p = 0.12). CON-
CLUSION: In this patient sample, interventions at both patient
and physician level are effective at reducing blood pressure.
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OBJECTIVES: Warfarin has highly variable dosing requirements
that are inﬂuenced by the CYP2C9 and VKORC1 genes. A recent
study suggested potential cost savings over $1 billion annually
to the US health care system if warfarin dose was guided by
genetic testing. The purpose of this study was to evaluate the
potential cost-effectiveness of warfarin pharmacogenomic testing
over a range of plausible scenarios. METHODS: A decision ana-
lytic model was developed to evaluate the clinical, patient, and
economic outcomes of adding genetic testing to anticoagulation
clinic standard of care for a hypothetical cohort of patients with
atrial ﬁbrillation. Epidemiological data for the risk of bleeds and
the effect of genetic variants were obtained from a systematic
evaluation of the literature. A lifetime horizon and payer per-
spective was utilized. In the testing arm, we assumed that the risk
of bleeding in CYP2C9 and VKORC1 variant patients decreased
by 50% and 25%, respectively, toward the risk of wild type
patients. Utility and cost data were obtained from the literature,
and the cost of the screening test was estimated based on cur-
rently available pharmacogenomic tests ($200). One-way sensi-
tivity analyses were performed to explore the range of plausible
results. RESULTS: The base-case incremental cost effectiveness
ratio (ICER) was $91,301/quality adjusted life year (QALY).
Varying the cost of genotyping between $100 and $550 resulted
in ICERs varying between $4,581/QALY and $403,822/QALY.
Varying the effectiveness for genotyping CYP2C9 between 
25% and 75% resulted in ICERs between $45,711 and
$339,781/QALY. Varying the effectiveness for genotyping
VKORC1 between 0%–50% resulted in an ICER between
$89,664 and $97,482. CONCLUSION: Genotyping patients for
CYP2C9 and VKORC1 are likely to increase costs, but have the
potential to be cost-effective depending on the effectiveness of
dose reductions and the cost of the test.
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OBJECTIVES: Because coronary artery disease is the leading
cause of death in the developed world, widespread implementa-
tion of evidence-based guidelines for the diagnosis of such
disease is an ongoing priority for medical professional societies.
Using a very large database comprising 2% of the U.S. adult pop-
ulation, we analyzed national patterns of cardiac diagnostic
testing. Our goal was to assess divergence from current clinical
guidelines in actual practice and evaluate the effects on costs 
and outcomes. METHODS: Our sample of commercial and
Medicare enrollees numbered 4,355,625 patients. Entry criteria
included age over 44 years, continuous enrollment from
2001–2003 excepting death, and a cardiac test with a diagnosis
of coronary artery disease, heart failure, or a related cardiac
symptom in 2001. Exclusion criteria included any cardiac diag-
nostic procedure or intervention in the 6 months preceding the
ﬁrst cardiac test. We measured the sequence of diagnostic pro-
cedures, interventions, cardiac events and treatment costs for
each patient. RESULTS: 42,223 patients met entry and exclusion
criteria and comprised our study group. 50% (21,075/42.223)
were male and 48% (20,208/42,223) were older than 64 years.
The prevalence of diabetes and hypertension was 32%
(13,352/42,223) and 69% (28,968/42,223). Most patients
(80%) completed an initial diagnostic pathway within 8 months
of the ﬁrst test. Patients had an average of 3.2 cardiac diagnos-
tic tests (95% conﬁdence interval 3.2–3.2, range 1–35) within 8
months of their initial test. 39% (16,354/42,223) had 2 or fewer
tests within 5 days and no further tests or events by 8 months.
Events evaluated included coronary artery bypass grafting 
(4% [1,793/42,223]), percutaneous coronary intervention 
(7% [3,138/42,223]), death (7% [2,964/42,223]), and hospital
admission for major adverse cardiac events (11%
[4,743/42,223]). CONCLUSION: Evaluation of diagnostic tests
and their sequences provide objective evidence to assess the
nature of divergence from expert guidelines and to calculate the
costs of cardiac disease evaluation.
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OBJECTIVES: To assess the formulary status of currently used
drugs, therapeutic guidelines and perceptions about the appro-
priateness of treatment of ADHF in community hospitals.
METHODS: A Web-based survey of pharmacy directors at com-
munity hospitals that were part of a national group purchasing
organization. RESULTS: One-hundred seven hospitals partici-
pated in the survey (response rate 47.1%). Diuretics like
furosemide and bumetanide were more commonly included
(100% and 94.4%, respectively) in hospital formularies than
torsemide (69.2%). Dopamine and dobutamine were more
common (94.4% each) on the formulary than milrinone
(68.2%). Nitroprusside and nitroglycerin were listed on the for-
mulary of more than 90% of institutions, while nesiritide was
listed on the formulary in only 48.6% of hospitals and placed
